Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CorMedix (CRMD) Gains from Investment Securities (2016 - 2025)

Historic Gains from Investment Securities for CorMedix (CRMD) over the last 12 years, with Q3 2025 value amounting to -$4.4 million.

  • CorMedix's Gains from Investment Securities changed N/A to -$4.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$3.0 million, marking a year-over-year decrease of 11183.97%. This contributed to the annual value of $289622.0 for FY2024, which is 4594.72% up from last year.
  • CorMedix's Gains from Investment Securities amounted to -$4.4 million in Q3 2025.
  • CorMedix's Gains from Investment Securities' 5-year high stood at $25.4 million during Q1 2023, with a 5-year trough of -$4.4 million in Q3 2025.
  • Moreover, its 5-year median value for Gains from Investment Securities was $3.1 million (2021), whereas its average is $4.6 million.
  • In the last 5 years, CorMedix's Gains from Investment Securities crashed by 9961.8% in 2024 and then surged by 94922.67% in 2025.
  • Over the past 5 years, CorMedix's Gains from Investment Securities (Quarter) stood at $6.5 million in 2021, then soared by 34.96% to $8.8 million in 2022, then soared by 189.77% to $25.4 million in 2023, then crashed by 99.79% to $53007.0 in 2024, then plummeted by 8320.39% to -$4.4 million in 2025.
  • Its last three reported values are -$4.4 million in Q3 2025, $247484.0 for Q2 2025, and $1.0 million during Q1 2025.